{"id":1409,"date":"2014-05-01T12:01:00","date_gmt":"2014-05-01T10:01:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/neues-zur-therapie-bei-vorhofflimmern"},"modified":"2022-03-17T14:12:57","modified_gmt":"2022-03-17T13:12:57","slug":"neues-zur-therapie-bei-vorhofflimmern","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2014\/neues-zur-therapie-bei-vorhofflimmern","title":{"rendered":"Neues zur Therapie bei Vorhofflimmern"},"content":{"rendered":"<p>Die US-amerikanischen kardiologischen Fachgesellschaften haben k\u00fcrzlich auf 123 Seiten neue Richtlinien zur Behandlung des Vorhofflimmerns (VHF) publiziert (1). Wir haben uns mit dieser Erkrankung in den letzten Jahren h\u00e4ufig besch\u00e4ftigt. W\u00e4hrend fr\u00fcher die therapeutischen Bem\u00fchungen und die Diskussion vor allem um die Fragen zur Rhythmisierung und Erhaltung des Sinusrhythmus kreisten (vgl. 2), sind in den [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die US-amerikanischen kardiologischen Fachgesellschaften haben k\u00fcrzlich auf 123 Seiten neue Richtlinien zur Behandlung des Vorhofflimmerns (VHF) publiziert (1). Wir haben uns mit dieser Erkrankung in den letzten Jahren h\u00e4ufig besch\u00e4ftigt. W\u00e4hrend fr\u00fcher die therapeutischen Bem\u00fchungen und die Diskussion vor allem um die Fragen zur Rhythmisierung und Erhaltung des Sinusrhythmus kreisten (vgl. 2), sind in den [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[185,127,137,1322,60,184,129,131,2305,178,491,1314,335,1312,3383,1421,187,68,134,3384,1328,1327,138,1423,183,2304,56,574,54,228,181,136],"class_list":["post-1409","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-absolute-arrhythmie","tag-amiodaron","tag-antikoagulanzien","tag-apixaban","tag-apoplektischer-insult","tag-arrhythmien","tag-beta-blocker","tag-betarezeptoren-blocker","tag-dabigatran","tag-digoxin","tag-diltiazem","tag-direkte-orale-antikoagulanzien","tag-disopyramid","tag-doak","tag-dronedaron","tag-flecainid","tag-herzrhythmusstoerungen","tag-hirninfarkt","tag-kalziumantagonisten","tag-katheterablation","tag-neue-orale-antikoagulanzien","tag-noak","tag-phenprocoumon","tag-propafenon","tag-rhythmusstoerungen","tag-rivaroxaban","tag-schlaganfall","tag-sotalol","tag-thromboembolie","tag-verapamil","tag-vorhofflimmern","tag-warfarin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1409","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1409"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1409\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1409"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1409"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1409"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}